Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 9/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24926317 | 0.86 | FAAH (0.36) | EPHX1GGPS1PPARAFAAHCA2 | |
| SCHEMBL27062672 | 0.84 | FAAH (0.33) | EPHX1GGPS1PPARAFAAHCA2 | |
| SCHEMBL18214479 | 0.83 | EPHX1 (0.37) | EPHX1GGPS1PPARAFAAHFDPS | |
| SCHEMBL19352779 | 0.83 | EPHX1 (0.37) | EPHX1GGPS1PPARAFAAHFDPS | |
| SCHEMBL19271990 | 0.82 | EPHX1 (0.36) | EPHX1GGPS1PPARAFAAHFDPS | |
| SCHEMBL21362003 | 0.80 | PPARA (0.38) | EPHX1GGPS1PPARAFAAHFDPS | |
| SCHEMBL19257391 | 0.79 | HPGD (0.36) | EPHX1GGPS1PPARAFAAHFDPS | |
| SCHEMBL19257453 | 0.79 | GRIA1 (0.39) | EPHX1GGPS1PPARAFAAHFDPS | |
| SCHEMBL19271944 | 0.77 | HPGD (0.35) | EPHX1GGPS1PPARAFAAHFDPS | |
| SCHEMBL18431222 | 0.77 | EPHX1 (0.33) | EPHX1GGPS1PPARAFAAHFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3R5, PIK3R1, PIK3R3 | EPHX1 3435/4885GGPS1 2119/4885PPARA 2607/4885 |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | EPHX1 3435/4885GGPS1 2119/4885PPARA 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.